Winmill & Co’s Medifast MED Stock Holding History

Winmill & Co’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-39,150	Closed	-$4.06M	–	80
2023 Q1	$4.06M	Hold	39,150	–	–	1.51%	30
2022 Q4	$4.52M	Hold	39,150	–	–	1.64%	29
2022 Q3	$4.24M	Hold	39,150	–	–	1.68%	25
2022 Q2	$7.07M	Hold	39,150	–	–	2.56%	13
2022 Q1	$6.69M	Hold	39,150	–	–	2.03%	17
2021 Q4	$8.2M	Hold	39,150	–	–	2.36%	12
2021 Q3	$7.54M	Hold	39,150	–	–	2.41%	11
2021 Q2	$11.1M	Hold	39,150	–	–	3.99%	2
2021 Q1	$8.29M	Hold	39,150	–	–	3.06%	5
2020 Q4	$7.69M	Hold	39,150	–	–	3.02%	2
2020 Q3	$6.44M	Hold	39,150	–	–	2.64%	4
2020 Q2	$5.43M	Hold	39,150	–	–	2.18%	6
2020 Q1	$2.45M	Hold	39,150	–	–	1.33%	28
2019 Q4	$4.29M	Buy	+39,150	New	+$3.79M	1.47%	15

Other funds holding MED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Winmill & Co's MED Position: Q2 2023 in Review

Winmill & Co sold out of Medifast (MED) in Q2 2023, closing a stake of 39,150 shares — an estimated $4.06M sold.

Winmill & Co first reported a position in MED in Q4 2019 and held it in 14 quarters. The position peaked at $11.1M in Q2 2021. 236 funds tracked by Wall St. Rank hold MED as of Q2 2023.

Winmill & Co reported no remaining Medifast position as of Q2 2023 after selling out during the quarter.
Winmill & Co sold 39,150 Medifast shares in Q2 2023, an estimated $4.06M.
Winmill & Co first reported a position in Medifast in Q4 2019 and held it in 14 quarters.
Winmill & Co's Medifast position peaked at $11.1M in Q2 2021.
236 funds tracked by Wall St. Rank held Medifast as of Q2 2023.

Based on Winmill & Co's 13F filing for Q2 2023, filed 11 Aug 2023.